Company news

Vortex Energy Corp. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Vortex Energy Receives Government Approval for Ground Gravity Survey at Robinsons River Salt Project

October 22, 2026

Vortex Energy Corp. Announces Extension of Marketing Program

October 15, 2026

Vortex Energy Commissions Hydrogen and Helium Study at Robinsons River Salt Project

October 5, 2026

Vortex Energy Completes Acquisition of the Meadows Project in Saskatchewan

October 1, 2026

Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial

September 22, 2026

Vortex Energy Enters Into Asset Purchase Agreement to Acquire the Meadows Project in Saskatchewan

September 17, 2026

Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain

September 15, 2026

Vortex Energy Engages Lonquist to Manage Ground Gravity Survey at the Robinsons River Salt Project

September 14, 2026

Vortex Energy Announces Plans for Ground Gravity Survey at the Robinsons River Salt Project

September 3, 2026

Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team

September 1, 2026

Vortex Energy Announces Final Ambient Noise Tomography Results for the Robinsons River Salt Project

August 18, 2026

Vertex Reports Second Quarter 2026 Financial Results

August 3, 2026

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

July 29, 2026

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: TriCo Bancshares (Nasdaq - TCBK), Twin Vee PowerCats Co. (Nasdaq -VEEE), Crinetics Pharmaceuticals, Inc. (Nasdaq - CRNX), Element Solutions Inc. (NYSE - ESI)

July 21, 2026

Vortex Energy Provides Corporate Update on Robinsons River Salt Project Technical Study

July 16, 2026

Vortex Energy Corp. Announces Closing of LIFE Offering

July 13, 2026

Vertex to Announce Second Quarter 2026 Financial Results on August 3rd

July 7, 2026

Vertex to Acquire Crinetics Pharmaceuticals

July 6, 2026

Vertex Announces US FDA Approval for Expanded Use of CASGEVY® for the Treatment of People Ages 2 Years and Older With Sickle Cell Disease or Transfusion-Dependent Beta Thalassemia

July 1, 2026

Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5-11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions

June 11, 2026

Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference

June 5, 2026

Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10

June 3, 2026

Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

June 1, 2026

Vertex Announces New Drug Submission for Suzetrigine Has Been Accepted for Review by Health Canada for the Treatment of Moderate-to-Severe Acute Pain in Adults

May 21, 2026

Vertex to Participate in Upcoming May Investor Conferences

May 11, 2026

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany

May 6, 2026

Vertex Reports First Quarter 2026 Financial Results

May 4, 2026

Vortex Energy Announces Intent to Advance Next Phase of Technical Work at the Robinsons River Salt Project and Engages Lonquist

April 30, 2026

Biotechs Racing to Translate Longevity Science Into Real Therapies -- And One Microcap Company Is Producing An Anti-Aging Protein From Genetically Modified, Encapsulated Cells

April 10, 2026

Vertex to Announce First Quarter 2026 Financial Results on May 4th

April 6, 2026

Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States

April 1, 2026

Anti-Aging Protein Research Takes a Step Forward with Cell Cloning

March 24, 2026

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy

March 9, 2026

Vertex to Present New Data on JOURNAVX® That Demonstrates Effective Pain Management Following Aesthetic and Reconstructive Procedures

March 5, 2026

Vortex Energy Announces Postponement of AGM

February 18, 2026

Vertex to Participate in TD Cowen 46th Annual Health Care Conference on March 3

February 17, 2026

Vertex Reports Fourth Quarter and Full Year 2025 Financial Results

February 12, 2026

Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets

January 26, 2026

Vortex Energy Highlights 2025 Technical Milestones Across Project Portfolio and Announces Adjournment of AGM to February 13, 2026

January 21, 2026

Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th

January 20, 2026

Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings

January 11, 2026

Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12

December 22, 2025

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions

December 6, 2025

Vertex to Participate in the Citi's 2025 Global Healthcare Conference on December 3

November 19, 2025

Vertex Presents Updated Phase 1/2 Data From RUBY-3 Study That Continue to Demonstrate Best-in-Class Potential for Povetacicept in Adults with IgA Nephropathy and Primary Membranous Nephropathy at American Society of Nephrology Kidney Week

November 8, 2025

Vortex Energy Corp. Announces Submission of Abstract for Presentation at the 2026 Canadian Hydrogen Convention

November 4, 2025

Vertex Reports Third Quarter 2025 Financial Results

November 3, 2025

Vertex to Participate in the UBS Global Healthcare Conference on November 11

October 27, 2025

Vertex Presents New Data Across Portfolio of Cystic Fibrosis Medicines Including ALYFTREK® at the North American Cystic Fibrosis Conference

October 23, 2025

Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week

October 17, 2025

Older news releases →

Decks

The 5 newest of 9 decks. Every deck is listed under its year.